Interstitial radiation: short-term palliation or curative therapy?

Area of Science:

• Oncology
• Radiation Oncology
• Urology

Background:

• Prostate cancer management faces challenges with surgical limitations and treatment side effects.
• Radioresponsiveness of prostate cancer suggests potential for radiation-based therapies.
• Interstitial brachytherapy aims to improve quality of life compared to other treatments.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of Iodine-125 (125I) seed implantation for clinically localized prostate cancer.
• To assess local control, survival rates, and functional preservation following 125I brachytherapy.

Main Methods:

• A thirteen-year retrospective study at Memorial Sloan-Kettering Cancer Center.
• Utilized interstitial implantation of 125I seeds for localized prostate cancer management.
• Analyzed actuarial survival and local control rates based on tumor stage and nodal status.

Main Results:

• Low morbidity and mortality associated with 125I seed implantation.
• High rates of functional preservation reported.
• Local control rates ranged from 80% to 90%.
• Nine-year actuarial survival rates were approximately 90% for T1, 60% for T2, and 45% for T3 lesions.
• Nine-year survival rates were 80% for node-negative and 50% for node-positive patients.

Conclusions:

• Iodine-125 (125I) seed implantation is a viable therapeutic option for localized prostate cancer.
• The technique demonstrates favorable outcomes in terms of survival and local control.
• Further research is needed to compare 125I brachytherapy with other treatment modalities.